---
title: Relationship of Skin Related SNP to Topical Skin Care Product
nct_id: NCT03446079
overall_status: COMPLETED
phase: NA
sponsor: HelicalCodeMD
study_type: INTERVENTIONAL
primary_condition: Genetics
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03446079.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03446079"
ct_last_update_post_date: 2023-07-03
last_seen_at: "2026-05-12T06:59:09.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Relationship of Skin Related SNP to Topical Skin Care Product

**Official Title:** Relationship of Skin Related Single Nucleotide Polymorphisms to Clinical Response to a Topical Skin Care Product

**NCT ID:** [NCT03446079](https://clinicaltrials.gov/study/NCT03446079)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 156
- **Lead Sponsor:** HelicalCodeMD
- **Collaborators:** 23andMe, Inc., Johnson & Johnson
- **Conditions:** Genetics, Skin Aging
- **Start Date:** 2018-03-19
- **Completion Date:** 2022-12-28
- **CT.gov Last Update:** 2023-07-03

## Brief Summary

Demonstrate the relationship between single nucleotide polymorphisms (SNP) and response to a topical skin care product.

## Detailed Description

Cross sectional study will utilize gene-specific candidate and genome wide association analysis to identify SNP's that may be associated with response to a topical product. Investigators and patients will be blinded to the genetic test results, and participants will be blinded to the skin product applied.

## Eligibility

- **Minimum age:** 21 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. At least 21 years old in general good health as determined by a health questionnaire.
2. Willingness to cooperate and participate by following study requirements and to report any adverse symptoms immediately.
3. Willingness to discontinue the use of all facial products other than the assigned test material and their regular brands of glamour products. The glamour products must be the subject's regular brand and have been used for a minimum of one month prior to the start of the study.
4. Willingness to remove make up at least 30 minutes prior to each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.
5. Willingness to avoid daily direct sun exposure on the face, whether natural or at tanning salons.
6. Willingness to discontinue antiaging cosmetics including alpha hydroxyacid products (including Lachydrin©), beta hydroxyacid products (including salicylic acid), poly hydroxyacid products, retinol products, acetyl glucosamine or other effective anti-aging topical products on the face 2 weeks prior to the start of the study and throughout the duration of the study.
7. Completion and signing of a Informed Consent and Enrollment form, HIPAA form, photo release form, medical intake, skin habits survey.
8. Willingness to complete all study assessments.

   \-

Exclusion Criteria:

1. Individuals who currently or in the last month have regularly used certain topical or oral medications which, in the opinion of the Investigators, may interfere with the study or that may expose study participants to unacceptable risks. Such products include oral prescription steroids or anti-inflammatories, topical steroids, or prescription skin treatment except for mild acne, as determined by the investigators.
2. Subjects who have a history of disease or current disease or regularly use topical or oral medications which, in the opinion of the Investigator, may interfere with the study or that may expose study participants to unacceptable risks. (i.e. oral or topical steroids or anti-inflammatories, etc.).
3. Uncontrolled metabolic disease such as diabetes, hyperthyroidism, or hypothyroidism or active Hepatitis, immune deficiency, or autoimmune disease as determined by the health questionnaire.
4. Pregnancy, nursing, or planning to become pregnant during the course of the study as determined by the health questionnaire.
5. History of skin cancer within the past 6 months.
6. Use of topical prescription retinoids for anti-aging including Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, or Differin® within 2 weeks prior to the start of the study.

   Use of oral retinoids within 6 months of the study start.
7. Subjects must not have had mid-depth or superficial chemical peel or other anti-aging procedures on the face (laser, intense pulsed light, injectable fillers microdermabrasion, etc.) within 2 months of the study start.
8. Known allergies or sensitivities to test material ingredients or any topical skin care product (i.e., alpha hydroxyacids, retinol, sunscreens, moisturizers, cleansers, masques, toners, etc.).
9. Individuals currently participating in other clinical testing.
10. Start of hormone use (including for birth control) or changed hormones less than three months prior to the start of the study. Qualified subjects must not be taking hormones or must have been taking them for at least three months prior to the study start.
```

## Arms

- **Primary Subjects** (EXPERIMENTAL) — Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.

## Interventions

- **Topical Anti Aging Cream** (OTHER) — Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.

## Primary Outcomes

- **Genetic Profile & Product Response** _(time frame: 6 weeks)_ — The primary endpoint being studied in this study is the association of the product response to the 17 candidate SNP genotypes.

## Secondary Outcomes

- **Novel SNP Identification** _(time frame: 6 weeks)_

## Locations (1)

- Halcyon Dermatology, Laguna Hills, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.halcyon dermatology|laguna hills|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03446079.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03446079*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*